Navigation Links
Fifth DSMB Meeting Supports Neurobiological Technologies' Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
Date:4/16/2008

EMERYVILLE, Calif., April 16 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced that after a scheduled review, an independent data safety monitoring board (DSMB) has recommended continuation of the company's two Phase 3 clinical trials to determine whether a brief intravenous infusion of Viprinex(TM) (ancrod) started within 6 hours of stroke onset improves functional outcome at 3 months. This is the fifth DSMB meeting for the Ancrod Stroke Program (ASP). The two trials are:

-- ASP-I, the Study of Acute Viprinex for Emergency Stroke: A Randomized,

Double-Blind, Placebo-Controlled Study of Ancrod in Subjects Beginning

Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke.

-- ASP-II- A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod

in Subjects Beginning Treatment within 6 Hours of the Onset of Acute,

Ischemic Stroke.

About Neurobiological Technologies:

Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate in phase 3 clinical testing is Viprinex(TM) (ancrod), a novel agent with multiple mechanisms that is specifically designed to expand the treatment window for treating acute ischemic stroke, one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. Its pipeline includes other drug candidates in early-stage development, including a first-of-its-kind drug for the treatment of Alzheimer's disease.

Forward Looking Statement:

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including uncertainties regarding the successful completion of clinical trials for Viprinex, as well as other risks detailed from time to time in our Annual Report of Form 10-K and other filings with the Securities and Exchange Commission. There can be no assurance that Viprinex will prove to be safe or effective in the ongoing Phase 3 trials or that it will receive regulatory approval for commercialization. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We undertake no obligation to update these forward-looking statements.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
2. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
3. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
4. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
5. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
6. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
7. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
8. PG500 Series Presented at the AACR Annual Meeting in San Diego
9. Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017  Newly published research from the CVS Health ... role a private retailer can play in restricting access ... online today in the American Journal of Public ... tobacco from all CVS Pharmacy stores reduced the number ... even greater impact on those who bought cigarettes exclusively ...
(Date:2/16/2017)... Calif. , Feb. 16, 2017  AcelRx ... specialty pharmaceutical company focused on the development and ... moderate-to-severe acute pain, announced that Vincent J. ... and a member of the company,s board of ... brings over two decades of experience leading executive ...
(Date:2/16/2017)... WASHINGTON , Feb. 16, 2017  Prescription pain ... emergency department visit are necessary for long-term opioid use ... the Feb. 16 th edition of The ... "Emergency physicians see more patients in acute pain ... Rebecca Parker , MD, FACEP, president of the American ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... MAP ... today that Karen Pilley has been promoted to Chief Executive Officer. , ... healthcare paradigm – a shift that demands the transition from pay-for-service to pay-for-performance ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... Chief Executive Officer, George Rogers, was named to Staffing Industry Analysts' 2017 "Staffing ... 100 honors those who have made notable contributions to the staffing industry over ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... Like most ... reduce readmissions. Driven in large part by the Hospital Readmission Reduction Program (HRRP), the ... a key focus area for hospitals across the nation. While many providers are struggling ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... planning assistance to families and business owners in and around the Hampton Roads ... to help prevent all forms of domestic violence. , There are multiple categories ...
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha Chigurupati ... years of research, development and clinical trials, the founder of Chigurupati Technologies has ... compound of FDA approved ingredients that when infused into alcohol, protect the consumer’s ...
Breaking Medicine News(10 mins):